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Development and validation of a UPLC-MS method for 
determination of atazanavir sulfate by the “analytical quality 
by design” approach
A UPLC-MS method for the estimation of atazanavir sul-
fate was developed using the “analytical quality by design” 
approach. The critical chromatographic quality attributes 
identified were retention time, theoretical plates and peak 
tailing. The critical method parameters established were 
percent of organic modifier, flow rate and injection volume. 
Optimization performed using Box-Behnken Design (BBD) 
established 10 % organic modifier, 0.4 mL min–1 flow rate 
and 6-µL injection volume as the optimum method condi-
tions. Atazanavir sulfate eluted at 5.19 min without any 
interference. Method validation followed international 
guidelines. The method has proven linearity in the range of 
10–90 µg mL–1. Recovery was between 100.2–101.0 % and 
precision within the accepted limits (RSD 0.2–0.7 %). LOD 
and LOQ were 2.68 and 8.14 µg mL–1, resp. Stress testing 
stability studies showed atazanavir sulfate to degrade under 
acidic and basic conditions. The suggested technique is 
simple, rapid and sustainable. It is, therefore, suggested for 
routine analysis of atazanavir sulfate.
Keywords: atazanavir sulfate, UPLC-MS, “analytical quality 
by design”
Atazanavir sulfate is the first protease inhibitor with a simplified dosing profile (1). 
Protease inhibitors are among the most potent classes of antiretroviral drugs; however, 
due to their pill burden and side effects, the prescribing choice has shifted to non-nucleo-
side reverse transcriptase inhibitors. Recent developments in the fixed-dose combination 
and highly active antiretroviral therapy has made atazanavir sulfate a promising drug (2, 
3). Atazanavir sulfate is chemically known as 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-
dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradec-
ane-dioic acid dimethyl ester. It has a favorable resistance profile that provides it with the 
advantage of being a first-line therapy drug (3). Having a large potential, the drug has been 
explored by determining its genotoxic impurities (4), determination in dried blood spot (5), 
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some bioanalytical methods (6, 7), development of stability indicating methods (8, 9), assay 
method (10) and pharmacokinetic studies (11–13). However, method development through 
the “analytical quality by design” (AQbD) approach has not been addressed.
Overcoming the challenges of one factor at a time (OFAT), the QbD approach has 
amended the pharmaceutical quality management system (14). QbD systematically builds 
quality within the process, eliminating quality testing at the end of the process (15). QbD 
approach commences by defining the quality targets and identifying the critical quality 
attributes. The paradigm advances by identifying the critical process and material para-
meters through sound risk assessment studies (16), further through the concept of experi-
mental designs/design of experiments (DOE); as a result, the multifactor effects on selected 
responses are observed. DOE also reduces the number of experiments to be performed 
when a large number of factors (inputs) are involved (14). The concept of QbD has been 
present in various industries since the 1970s but was introduced into the pharmaceutical 
industry in 2004 through Pharmaceutical cGMPs for the 21st Century initiative (17); it is 
also reflected in ICH Q8-Q10 guidelines (18–20). The QbD approach has been adopted as 
“analytical quality by design” (AQbD) for analytical method development with peripheral 
alterations in terminologies (21).
The focus of this paper is therefore to maneuver the paramount advantages of QbD to 
analytical method development using ultra performance liquid chromatography-mass 
spectrometry (UPLC-MS). Method development through the AQbD approach for the de-
termination of atazanavir sulfate constitutes the novelty of this paper. Unlike the existing 
methods for determination of atazanavir sulfate, the current method avoids the use of 




The gift sample of atazanavir sulfate, active pharmaceutical ingredient, was received 
from Laurus Labs, India. Atazanavir sulfate capsules, Atazor 300 mg, from Emcure Phar-
maceuticals Ltd., India, were obtained from the local market. Thermo Fisher Scientific, 
USA, furnished LCMS grade acetonitrile. GR grade ammonium acetate was from Merck, 
Germany. HPLC type I water was from the Millipore Direct-Q® 3 UV water purification 
system, Merck Millipore, Germany.
Chromatographic conditions and apparatus
Acquity UPLC® (Waters, USA) using a reverse-phase Acquity UPLC BEH C18 (1.7 µm, 
1 mm x 50 mm) column coupled in-line with a Synapt G2 (Waters, USA) mass spectrometer 
aided by a high resolution quantitative time-of-flight (QuanTof™) analyzer and featuring 
an ultra-fast electron multiplier, hybrid analog-to-digital (ADC) detector, was used for all 
chromatographic separations. Electrospray ionization interface in positive mode directed 
column eluent to the mass spectrometer. The mass spectrometer operated in sensitivity 
mode using capillary voltage of 1.8 kV and  cone voltage of 17 V. The desolvation gas flow 
rate was 300 L h–1, while the source and desolvation gas temperature were 100 and 200 °C, 
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resp. The gradient mode mobile phase was composed of 10 mmol L–1 ammonium acetate 
as solvent A and acetonitrile as solvent B. Organic modifier percent, mobile phase flow rate 
and injection volume were varied according to the experimental runs from DOE. 
Preparation of standard stock solution
Standard stock solution of 1.0 mg mL–1 was obtained by dissolving accurately weighed 
atazanavir sulfate in water. Serial dilutions of the standard stock solution gave working 
standards between 10 and 100 µg mL–1. Working standards were filtered using 0.2-µm 
Phenex PTFE syringe filters (Phenomenex, USA) before being injected.
Method development using the AQbD approach 
The first step in the AQbD approach is to define the objectives of the method, collec-
tively termed as analytical target profile (ATP)/quality target method profile (QTMP) (22–
24). The ATP of the current method was to develop a simple, accurate, precise, robust and 
specific method meeting the critical quality attributes (CQAs). CQAs are the most vital 
parameters that, within their defined limits, ensure the quality of the method (29). The 
CQAs identified for the suggested UPLC-MS method development were retention time, 
theoretical plates and peak tailing. The acceptance criterion for theoretical plates was 
> 2000 and < 2 for peak tailing (26, 27). Further, risk factors identification through initial 
trials, risk analysis through Ishikawa/fish bone diagram and evaluation by failure mode 
and effect analysis (FMEA) were used to uncover the high risk factors as critical method 
parameters (CMPs). 
Initial screening of factors through fraction factorial design (FFD). – Initial screening of fac-
tors/method parameters aids to discover the CMPs that significantly cause variations in 
CQAs and eliminates factors which are just noise. Fraction factorial design (FFD), resolu-
tion IV with one generator (24–1) from Design Expert® v.11.0 software produced eight ex-
perimental runs for the initial screening of four factors at two levels. The factors at their 
low and high levels were organic modifier: 10 and 30 %, flow rate: 2 and 6 mL min–1, injec-
tion volume: 0.2 and 0.6 µL and column temperature: 25 and 45 °C. Using Pareto charts and 
model significance values, the significant factors were resolved. 
Optimization of selected factors using the Box-Behnken design (BBD). – The significant fac-
tors, organic modifier (at 10 and 30 %), flow rate (2 and 6 mL min–1) and injection volume 
(0.2 and 0.6 µL), were optimized at their low and high levels using BBD; they produced 17 
experimental runs. These experiments were performed using 50 µg mL–1 working stan-
dard solution of atazanavir sulfate. The results were analyzed by goodness of fit (R2), 
p-values, adjusted R2 and predicted R2, and the lack-of-fit values by Design Expert® v.11.0 
software. Variations in CQA were comprehended through contour plots and 3D graphs. 
Numerical optimization was used to optimize and select the method conditions best fit-
ting the CQAs with desirability near one. Criteria for optimization of retention time and 
peak tailing were selected to be “in range” of their minimum to maximum values obtained 
during the experiments, while the criterium was set to the maximum value for theoretical 
plates. Graphical optimization with 99 % tolerance assisted exploring the design space 
within the set criteria.
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Analytical method validation
Following ICH Q2(R1) guidelines (28), parameters like linearity, accuracy, precision, 
limit of detection (LOD), limit of quantification (LOQ) and selectivity were assessed during 
the method validation. AQbD approach provides the advantage of establishing the design 
space, a region within which any changes to factor (CMP) values do not significantly affect 
the method development, thus, incorporating robustness into the process and, therefore, 
testing of robustness at the end of method development can be omitted (18). 
Linearity. – Working standard solutions prepared in the range of 10–100 µg mL–1 were 
filtered through a 0.2-micron syringe filter and injected into the chromatograph, each in 3 
replicates. Total ion chromatograms (TIC) were obtained and the calibration curve was 
plotted to establish the linear relationship by the least squares method.
Accuracy. – Accuracy was tested using the standard addition method. The capsule 
formulation sample was spiked with a known amount of the active pharmaceutical ingre-
dient at 80 % (40 µg mL–1), 100 % (50 µg mL–1) and 120 % (60 µg mL–1). The resultant solution 
was analyzed in six replicates. Percentage recoveries were calculated and reported (Table 
III). 
Precision. – The intra-day and intermediate (inter-day) precision were calculated from 
the peak areas of 40, 50 and 60 µg mL–1 working standard solutions of atazanavir sulfate, 
injected on the same day and on two consecutive days, resp. (n = 6). Similarly, precision of 
the formulation analysis using 40, 50 and 60 µg mL–1 solutions of Atazor was measured.
LOD and LOQ. – LOD and LOQ were calculated using calibration curve data, follow-
ing the formula LOD = 3.3xSD/slope and LOQ = 10xSD/slope, where SD is the standard 
deviation of the regression line (29, 30).
Selectivity. – Selectivity of the method was demonstrated by injecting the blank, work-
ing standard solution and sample (commercial formulation) solution and monitoring the 
elution of analyte.
Stability testing (stress conditions)
Pursuant to ICH Q1A (R1) and ICH Q1 B guidelines (31, 32), stress testing of the drug 
substance can help identify the likely degradation products, which can in turn help estab-
lish the degradation pathways and the intrinsic stability of the molecule and validate the 
stability indicating power of the analytical procedure used.
Acid, base and thermal (moist heat) degradation. – Ten mg of atazanavir sulfate was dis-
solved in 10 mL 0.1 mol L–1 HCl, 0.1 mol L–1 NaOH and water, resp., in a round bottom flask 
and refluxed at 80 °C for 60 min. Samples were collected at 60 min and cooled to room 
temperature (28 °C). The acid and base degraded samples were then neutralized with 0.1 
mol L–1 NaOH and 0.1 mol L–1 HCl, resp. All samples were further diluted with water to 50 
µg mL–1, sonicated for 5 min, filtered and injected into the UPLC-MS system. 
Oxidative degradation. – Ten mg of atazanavir sulfate reacted with 10 mL of 3 % and 30 
% H2O2 separately in two round bottom flasks at room temperature (28 °C) for 60 min. 
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Samples collected after 60 min were cooled to room temperature (28 °C), diluted with water 
to 50 µg mL–1, sonicated for 5 min, filtered and injected into the UPLC-MS system.
Photolytic degradation. – Ten mg of atazanavir sulfate in a clean quartz tube was placed 
under UV light (320 nm) for 1 day. The drug was sampled thereafter, dissolved in water to 
a concentration of 1.0 mg mL–1 and further to 50 µg mL–1. This solution was sonicated for 
5 min, filtered and injected into UPLC-MS.
RESULTS AND DISCUSSION
Risk assessment studies
In order to develop a method within the acceptable range of CQAs, it is essential to 
have a thorough understanding of the method parameters and their effects. A risk assess-
ment study methodically identifies the factors/parameters that can have a substantial ef-
fect on the CQAs. ICH Q9 lists 9 risk management tools (19), of which the Ishikawa/fish-
bone diagram and failure mode and effect analysis (FMEA) are extensively used in the 
QbD approach (33). The Ishikawa diagram/fishbone diagram dissects the method develop-
ment process into various fractions such as men, material, method, etc., and each fraction 
provides an insight into factors/parameters that can affect the CQAs. Further, FMEA aids 
to rank and prioritize these factors into low, medium, and high risks based on a composite 
score called the risk priority number (RPN). The RPN is calculated based on the impact of 
risk on the method, frequency of occurrence and the ability to detect the failure (impact * 
occurrence * detectability) (14).
In the present method, initial trials, Ishikawa diagram/fishbone diagram (Fig. 1) and 
FMEA tools, resp., identified, analyzed and prioritized the risk factors associated with the 
method development process. Using the knowledge from initial trails, identified risks were 
evaluated for their impact, occurrence, and detection, to calculate the RPN. Factors that 
Fig. 1. Ishikawa diagram/fishbone diagram for estimating the parameters affecting CQAs. 
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Table I. Identifying high risk factors through the risk priority number (RPN)























Solubility Recovery, peak area, theoretical plates 3 1 4 12
Sonication Separation quality 1 1 4 4
Ionization Peak detection 4 1 1 4
Organic modifier Retention time, separation quality 4 1 4 16
Organic modifier portion Retention time, separation quality, peak area 5 5 4 100
Injection volume Peak area, separation quality, peak area 5 5 4 100
Separation mode Retention time, separation quality, peak area 3 1 4 12
Flow type Retention time 3 1 4 12
Flow rate Retention time, separation quality, peak area 5 5 4 100
Column temperature Separation quality 4 5 4 80
Column type Retention time, separation quality, peak area 4 1 4 16
RPN – risk priority number: < 43 (low risk factors), 44–83 (medium risk), > 84 (high risk).


















15 1 20 0.4 4 4.92 6556 0.82
16 2 20 0.4 4 4.91 6488.7 0.81
12 3 20 0.6 6 4.37 7861.3 0.70
10 4 20 0.6 2 4.37 6892 0.74
6 5 30 0.4 2 4.29 6331 0.69
13 6 20 0.4 4 4.7 6808.5 0.79
1 7 10 0.2 4 7.22 6409.51 1.01
5 8 10 0.4 2 5.2 7642.93 0.761
7 9 10 0.4 6 5.21 9028 0.78
4 10 30 0.6 4 3.6 6764 0.63
3 11 10 0.6 4 4.71 6034.72 0.61
11 12 20 0.2 6 6.4 6688.4 1.03
8 13 30 0.4 6 4.29 7380.47 0.64
9 14 20 0.2 2 6.37 5438.1 1.09
14 15 20 0.4 4 4.92 6556 0.78
17 16 20 0.4 4 4.92 6556 0.81
2 17 30 0.2 4 5.86 3982.8 0.82
CQAs – critical quality attributes  
a Per column length.
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Fig. 2. Pareto chart representing the significance of risk factors on chosen CQAs: a) retention time, b) 
theoretical plates and c) peak tailing.
could have high severity (impact), high occurrence (probability) and low detectability were 
assigned the value of 5 on a scale of 1–5 while factors showing low severity, low occurrence 
and high detectability scored near 1. The RPN values classified the organic modifier per-
cent, flow rate, and injection volume as highrisk factors while column temperature was a 
mediumrisk factor (listed in Table I). Further, these factors were screened using DOE. 
Initial screening of factors through fraction factorial design (FFD). – The four factors 
screened through FFD (24–1) showed a parallel relation between the main effects. Proving 
the lack of interactions, their evaluation followed the first-order polynomial equation given 
as follows: 
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Fig. 3. 3D surface plots for responses: a) retention time, b) theoretical plates and c) peak tailing.
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 Y = β0 + β1*X1 + β2*X2 + β3*X3 + β4*X4
where β0 is the intercept and β1–β4 are coefficients of each factor, X being the factor value 
and Y is the response. The results were analyzed using a Pareto chart as shown in Fig. 2. 
It shows that the flow rate and organic modifier had a significant effect on retention time 
and theoretical plates, while the flow rate and injection volume influenced peak tailing. 
High R2 values for retention time (0.9895), theoretical plates (0.9945) and peak tailing 
(0.9556) inferred that these factors caused significant variations in the CQAs; hence, opti-
mization was carried out using these three factors. Column temperature did not influence 
the CQAs significantly and thus it was set to an intermediate value of 35 °C during 
optimization experiments. Screening of factors prior optimization helps reduce the ex-
perimental burden and errors. 
Optimization and design space. – The results presented in Table II revealed quadratic 
relations between the CMPs and the CQAs; thus, evaluation followed the second-order 
polynomial equation:
 Y = β0 + β1*X1 + β2*X2 + β3*X3 + β4*X1X2 + β5*X2X3 + β6*X1X3 β7*X12 + β8*X22 + β9*X32
where β0 is the intercept and β1–β9 are coefficients of each term, X being the factor value 
and Y is the response. 
The results (Table II) were analyzed by analysis of variance (ANOVA) and fit statistics 
by observing their p-values and goodness of fit (R2), resp. The R2 values for retention time 
(0.9883), theoretical plate (0.9848) and peak tailing (0.9904), all being close to one and the 
p-values observed to be < 0.05, justified the significant influence of CMPs on the variation 
in CQAs (p < 0.05 rejects the null hypothesis and accepts the alternative hypothesis that 
factors are significant). The difference between the adjusted R2 and predicted R2 found to 
be less than 0.2 indicated the absences of inflated factor inclusion in the model. Adjusted 
R2 values decrease if insignificant factors are included in the model, causing an increased 
difference between adjusted and predicted R2 values, which is an indication of a model 
with unnecessary factors. The lack of fit being not significant proved that the model was 
safe to explore the design space/method operable design region (MODR).
Influence of CMPs on retention time, theoretical plates and peak tailing was in curvi-
linear fashion as observed through the contour plots and 3D surface plots (Fig. 3). The 3D 
surface plots in Fig. 3a show long retention time towards lower organic modifier percent 
and short retention time towards higher organic modifier percent at increased flow rate. 
Theoretical plates were high in case of lower organic modifier percent, flow rate around 
0.4 mL min–1 and higher injection volume, as shown in Fig. 3b; Fig. 3c shows lowered peak 
tailing at low and high organic modifier percent at a flow rate of >0.4 mL min–1.
Numerical optimization was used to figure out the method conditions with desirabil-
ity near one. The criteria during optimization were set to be “in range” of minimum to 
maximum values of the retention time and peak tailing obtained from 17 experiments, 
while maximum for theoretical plate. From the 2D contours plots in Fig. 4, we can interpret 
the area with high desirability (orange), low (blue) to high (orange) retention time, high 
(orange) theoretical plates and low (blue) peak tailing. Cumulatively from the results of 3D 
surface plot, numerical optimization and contour plots, the optimized method conditions 
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Fig. 4. 2D contour plots for desirability, retention time, theoretical plates/column length and peak 
tailing.
Fig. 5. Overlay plot showing the method operable design region.
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established were 10 % organic modifier, 0.4 mL min–1 flow rate and 6-µL injection volume. 
Mobile phase was run in the following gradient percentage of acetonitrile, organic modi-
fier: initial 10 %, 4–5 min 50 %, 7–8 min 10 %. Graphical optimization was used to explore 





















40.0 90.8 0.2 100.4
50.0 100.8 0.2 100.2
60.0 111.2 0.3 100.5
Concentration found (µg mL–1)b RSD (%)
Intra-day Inter-day Intra-day Inter-day
40.0a 40.2 40.3 0.3 0.5
50.0a 50.3 50.3 0.7 0.7




Concentration found (µg mL–1)b RSD (%) Model recovery (%)
Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day
40.0 40.4 40.3 0.5 0.7 101.0 100.8
50.0 50.3 50.1 0.6 0.6 100.6 100.2
60.0 60.4 60.2 0.5 0.7 100.7 100.3
a Atazor capsules; concentration upon label claim.
b Mean value, n = 6.
Table IV. Comparison of the new method with the existing ones
Mobile phase Retention time (min) Ref.
Phosphate buffer (pH 6)-acetonitrile (43:57, V/V) 16.20 34
Solvent A: KH2PO4 buffer (0.02 mol L–1, pH 3.5), solvent B: acetonitrile 12.5 35
Mobile phase A: 0.01 mol L–1 KH2PO4 (pH 3.6), mobile phase B: 
acetonitrile 9.18 36
MeOH-H2O (9:1, V/V) pH 3.55 (with HAc) 8.32 8
55 % acetonitrile, 45 % water, 0.15 % HAc, 4 mmol L–1 NH4Ac 8.30 37
0.02 mol L–1 NH4H2PO4 buffer-acetonitrile-MeOH (30:25:45, V/V), pH 
2.5 (with H3PO4)
3.00 9
Solvent A: 10 mmol L–1 NH4Ac, solvent B: acetonitrile 5.19 This paper
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Fig. 6. a) TIC of atazanavir sulfate eluted at 5.19 min, b) mass spectrum of the eluted peak.
the design space/MODR. Design space (yellow area) indicated the region where changes 
to the optimized conditions will be tolerated and will be within the operable quality (Fig. 
5), thus, confirming the robustness of the method for the intended use.
Fig. 7. TIC of: a) mobile phase (blank), b) standard atazanavir sulfate, c) commercial capsule of ata-
zanavir sulfate and d–f) their respective mass spectra.
29
C. Saha et al.: Development and validation of a UPLC-MS method for determination of atazanavir sulfate by the “analytical quality 
by design” approach, Acta Pharm. 70 (2020) 17–33.
 
Fig. 8. a) BPI chromatogram of acidic degradation of atazanavir sulfate, b) mass spectra of eluted 
peaks from acidic degradation of atazanavir sulfate, c) BPI chromatogram of basic degradation of 
atazanavir sulfate, d) mass spectra of eluted peaks from basic degradation of atazanavir sulfate, e–h) 
BPI chromatograms of thermal, photolytic, 3 % H2O2 oxidative and 30 % H2O2 oxidative degradation 
of atazanavir sulfate, resp.
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Under optimized conditions, atazanavir sulfate was eluted at 5.19 min; the 705 m/z 
value from the mass spectrum confirmed the presence of atazanavir sulfate without any 
interference. Fig. 6a shows the total ion chromatogram (TIC) and Fig. 6b the mass spectrum 
of the eluted peak. 
Method validation
The developed analytical method was linear in the range of 10–90 µg mL–1. The cali-
bration plot statistically proved the linearity (y = 56.18x + 0.3573; R² = 0.9999) indicating 
good linear fit. The method was reported to be accurate with recovery between 100.2 – 
101.0 % and precise with RSD ranging from 0.2–0.7 % (Table III). Calculated LOD and LOQ 
of atazanavir sulfate were 2.68 and 8.14 µg mL–1, resp. The method was shown to be selec-
tive with the analyte being identified as a sharp peak at 5.19 min both in standard and 
sample solutions without any interference from the blank (Fig. 7). The optimized and 
validated method proved to be better than several existing liquid chromatographic meth-
ods in terms of retention time and simple mobile phase composition (see Table IV).
Further, the systematic approach to optimized method conditions and statistical jus-
tification make the entire process distinct from the regular practice.
The proposed method was applied to the assay of a commercial capsule formulation. 
The mean % assay was 101.0 % of the declared amount with RSD of 0.5 % (n = 6).
Stability testing (stress testing)
Stress testing studies showed atazanavir sulfate to degrade under acidic and basic 
conditions while being stable under thermal, oxidative and photolytic experimental condi-
tions. Fig. 8 shows the results of degradation through base peak intensity (BPI), for it is 
much cleafer to view all degradation peaks unlike in TIC.
CONCLUSIONS
Unlike the existing approaches for method development, the AQbD approach to 
method development made the entire process rational, systematic and embedded robust-
ness within the method. The proposed method achieved the ATP by systematically iden-
tifying the risk factors and optimizing them to perceive the method conditions best fitting 
the defined CQAs. The method gave a detailed insight into the benefits of screening factors 
before optimization, thus reducing significant factors to organic modifier percent, flow rate 
and injection volume. Optimization using experimental design founded the method con-
ditions, which was justified by statistical analysis. Following the established design space 
during method development can control experimental errors. Statistical significance of the 
method conditions along with satisfactory alignment to validation guidelines made the 
method sustainable and reflected its reliability. This approach shows that methodical plan-
ning and orderly execution can reduce the risk, experimental burden and errors, and thus 
its application to various research areas is foreseen. 
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Acronyms, abbreviations, symbols. – Ac – acetate, ADC – analog-to-digital, AQbD – analytical quality 
by design, ATP – analytical target profile, BPI – base peak intensity, BBD – Box-Behnken design, BEH 
– ethylene bridged hybrid, CMPs – critical method parameters, CQAs – critical quality attributes, 
DOE – design of experiments, FMEA – failure mode and effects analysis, FFD – fraction factorial 
design, MeOH – methanol, MODR – method operable design region, OFAT – one factor at a time, 
PTFE – polytetrafluoroethylene, QbD – quality by design, QTMP – quality target method profile, RPN 
– risk priority number, TIC – total ion chromatograms 
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